Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 5.54%
As of Thursday, July 09, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.54%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Commentary & Analysis
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 5.68%
As of Tuesday, June 23, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.68%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 6.78%
As of Monday, June 22, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 6.78%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 6.26%
As of Friday, June 05, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 6.45%
As of Tuesday, June 02, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 6.45%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $743.0 | $569.9 | 42% |
|
| Shares Out (Mil) | 128.8 | 44.8 | 68% |
|
| Institutional Ownership | 96.4% | 84.6% | 70% |
|
| Float (Mil) | 113.1 | 45.1 | 64% |
|
| Beta | 0.78 | 0.67 | 46% |
|
| Avg Daily Volume (000s) | 1,558 | 294 | 78% |
|
| Price Change (52-week) |
243.2% | 65.2% | 98% |
|
| Growth | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.7% | 6.7% | 30% |
|
| Net Income (5yr) | (4.9%) | (2.0%) | 34% |
|
| EPS (5yr) | 15.1% | 14.9% | 56 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 34.4% | (14.9%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 9 | |
| Current EPS | ($0.160) | ($0.655) | ($0.829) | |
| Month Ago EPS | ($0.160) | ($0.655) | ($0.829) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.157) | ($0.640) | ($0.756) | |
| Year/Year Chg | 3.9% | 23.6% | 57.4% | |
| Financials | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $230 | 8% |
|
| Net Income (TTM) (Mil) | ($70) | ($11) | 14% |
|
| EPS (TTM) | ($0.561) | ($0.600) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($52) | ($6) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $4 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $7 | 19% |
|
| Enterprise Value (Q1) (Mil) | $493 | $493 | 34% |
|
| Valuation | ACRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.17 | 2.89 | 79% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (668.2%) | 65.9% | 0% |
|
| Net Margin | (832.6%) | (0.2%) | 0% |
|
| ROA | (35.1%) | (25.5%) | 15% |
|
| ROE | (48.4%) | (21.4%) | 16% |
|
| Liabilities to Assets | 27.7% | 35.5% | 19% |
|
| F-Score | 3 | 3 | 19% |
|
Aclaris Therapeutics, Inc. did not pass any screens on 7/30/2026.
